In This Article:
PhaseV has formed a strategic collaboration with Alimentiv to support the design and execution of adaptive clinical trials targeting gastrointestinal (GI) conditions.
This collaboration concentrates on trials for conditions like celiac, inflammatory bowel disease (IBD), and eosinophilic gastrointestinal disease (EGID).
Randomised control trials (RCTs) in GI research face multiple obstacles, including patient diversity, high placebo responses, protracted timelines, and escalating costs.
These issues can impede the progress of discovering new treatments. Adaptive trial designs, utilising real-time data, present a solution to these challenges by refining trial design and execution as the study progresses.
The partnership will integrate PhaseV's adaptive clinical trial technology with Alimentiv's comprehensive GI contract research organisation (CRO) services.
This is set to facilitate the ideal design and execution of adaptive trials, aiding biotech and pharmaceutical companies in surmounting the inherent difficulties of traditional trial methodologies.
PhaseV's technology harnesses advanced causal inference and machine learning (ML) to identify subtle patterns in clinical data, providing actionable insights for planning future trial stages.
This approach enables the optimal design and closed-loop adaptive trial execution, improving the likelihood of successful outcomes.
PhaseV co-founder and CEO Raviv Pryluk said: "GI clinical trials have historically been limited by challenges such as patient variability, complex disease mechanisms, and a lack of validated biomarkers. These challenges often complicate efficacy assessments of new treatments and lead to trial failure.
"Aligning our ML platform with Alimentiv's GI trial leadership will help trial sponsors overcome these challenges, enabling more robust trial designs and execution that increase the likelihood of success."
Alimentiv, which specialises in GI-focused clinical trials and medical research, brings extensive experience to the partnership.
In April last year, PhaseV partnered with Quanticate to expedite clinical development programmes. This collaboration was aimed at assisting biotech firms and sponsors in conducting more advanced and efficient clinical trials through the use of adaptive trial designs.
"PhaseV and Alimentiv to support execution of adaptive clinical trials for GI" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.